Everence Capital Management Inc. Has $244,000 Stock Holdings in NeoGenomics, Inc. (NASDAQ:NEO)

Everence Capital Management Inc. trimmed its position in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 7.3% during the third quarter, HoldingsChannel.com reports. The firm owned 16,530 shares of the medical research company’s stock after selling 1,310 shares during the period. Everence Capital Management Inc.’s holdings in NeoGenomics were worth $244,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the company. Blue Trust Inc. lifted its stake in shares of NeoGenomics by 42.3% in the third quarter. Blue Trust Inc. now owns 3,318 shares of the medical research company’s stock worth $46,000 after acquiring an additional 987 shares during the period. Creative Planning lifted its stake in shares of NeoGenomics by 42.3% in the third quarter. Creative Planning now owns 23,547 shares of the medical research company’s stock worth $347,000 after acquiring an additional 7,004 shares during the period. Inspire Investing LLC lifted its stake in shares of NeoGenomics by 12.0% in the third quarter. Inspire Investing LLC now owns 28,094 shares of the medical research company’s stock worth $414,000 after acquiring an additional 3,006 shares during the period. Handelsbanken Fonder AB lifted its stake in shares of NeoGenomics by 12.0% in the third quarter. Handelsbanken Fonder AB now owns 25,200 shares of the medical research company’s stock worth $372,000 after acquiring an additional 2,700 shares during the period. Finally, SG Americas Securities LLC acquired a new position in shares of NeoGenomics in the third quarter worth approximately $312,000. 98.50% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on NEO. Benchmark reaffirmed a “buy” rating and issued a $18.00 price objective on shares of NeoGenomics in a research note on Tuesday, September 24th. Needham & Company LLC reiterated a “buy” rating and issued a $19.00 target price on shares of NeoGenomics in a report on Wednesday, September 25th. Finally, Stephens reiterated an “overweight” rating and issued a $19.00 target price on shares of NeoGenomics in a report on Tuesday, July 30th. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $19.89.

NeoGenomics Trading Up 0.7 %

NASDAQ NEO opened at $13.22 on Wednesday. The company has a market cap of $1.69 billion, a price-to-earnings ratio of -20.03 and a beta of 1.19. NeoGenomics, Inc. has a 52 week low of $12.77 and a 52 week high of $21.22. The business has a 50 day moving average price of $15.26 and a 200-day moving average price of $14.76. The company has a quick ratio of 1.93, a current ratio of 2.01 and a debt-to-equity ratio of 0.37.

NeoGenomics (NASDAQ:NEO) last released its quarterly earnings data on Monday, July 29th. The medical research company reported $0.03 EPS for the quarter. The firm had revenue of $164.50 million during the quarter, compared to the consensus estimate of $161.82 million. NeoGenomics had a negative return on equity of 2.72% and a negative net margin of 12.50%. The company’s quarterly revenue was up 12.0% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.09) earnings per share. As a group, equities analysts expect that NeoGenomics, Inc. will post -0.21 earnings per share for the current fiscal year.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.